Equities research analysts expect Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) to announce earnings per share (EPS) of ($0.57) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kiniksa Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.54). Kiniksa Pharmaceuticals reported earnings of ($0.88) per share during the same quarter last year, which indicates a positive year over year growth rate of 35.2%. The business is scheduled to issue its next earnings report on Thursday, March 5th.
According to Zacks, analysts expect that Kiniksa Pharmaceuticals will report full-year earnings of ($2.99) per share for the current fiscal year, with EPS estimates ranging from ($3.02) to ($2.96). For the next year, analysts expect that the company will post earnings of ($2.63) per share, with EPS estimates ranging from ($2.76) to ($2.50). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Monday, October 28th. The company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.23.
Kiniksa Pharmaceuticals stock traded up $1.55 during mid-day trading on Thursday, hitting $12.92. 629,581 shares of the company’s stock were exchanged, compared to its average volume of 139,347. The firm has a market capitalization of $582.26 million, a P/E ratio of -3.70 and a beta of -1.02. Kiniksa Pharmaceuticals has a fifty-two week low of $5.01 and a fifty-two week high of $28.90. The company’s 50 day simple moving average is $8.09 and its 200-day simple moving average is $10.57.
Several institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. Point72 Asset Management L.P. boosted its position in shares of Kiniksa Pharmaceuticals by 300.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 140,000 shares of the company’s stock valued at $1,191,000 after acquiring an additional 105,000 shares during the last quarter. State Street Corp increased its holdings in shares of Kiniksa Pharmaceuticals by 4.2% during the 3rd quarter. State Street Corp now owns 229,477 shares of the company’s stock valued at $1,953,000 after purchasing an additional 9,282 shares in the last quarter. First Manhattan Co. increased its holdings in shares of Kiniksa Pharmaceuticals by 68.3% during the 2nd quarter. First Manhattan Co. now owns 63,976 shares of the company’s stock valued at $866,000 after purchasing an additional 25,970 shares in the last quarter. Citadel Advisors LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 195.8% during the 2nd quarter. Citadel Advisors LLC now owns 372,287 shares of the company’s stock valued at $5,041,000 after purchasing an additional 246,442 shares in the last quarter. Finally, Morgan Stanley increased its holdings in shares of Kiniksa Pharmaceuticals by 54.2% during the 2nd quarter. Morgan Stanley now owns 60,098 shares of the company’s stock valued at $814,000 after purchasing an additional 21,130 shares in the last quarter. 29.85% of the stock is currently owned by hedge funds and other institutional investors.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Featured Story: The basics of gap trading strategies
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.